Research compounds
Amylin
IAPP, islet amyloid polypeptide
Amylin is a 37-amino-acid hormone co-secreted with insulin by pancreatic beta cells. Native human amylin aggregates into amyloid fibrils, which is why the approved drug pramlintide is a modified analogue rather than the hormone itself.
Also known as: IAPP, islet amyloid polypeptide
- Status
- Amylin is a research compound and not approved by the FDA for human use.
- Evidence
- Early human data. Only small or early-phase studies in people so far.
- Half-life
- Approximately 13 minutes.
- How it's taken
- Not used therapeutically in native form
- Mechanism
- Incretin (GLP-1 / GIP / glucagon / amylin)
- Pathways
- Amylin
How Amylin works
Amylin acts at amylin receptors — calcitonin receptors complexed with receptor activity-modifying proteins — in the area postrema. It slows gastric emptying, suppresses postprandial glucagon secretion and promotes satiety, complementing insulin's action on glucose disposal. Human amylin is intrinsically amyloidogenic, forming the islet amyloid deposits characteristic of type 2 diabetes.
What research has looked at
- It is the second beta cell hormone, and its deficiency in type 1 diabetes explains why insulin replacement alone does not restore normal postprandial glucose control.
- Its pharmacology is validated by two approved-or-advanced products: pramlintide, and cagrilintide as the amylin arm of CagriSema.
- The amylin pathway is entirely separate from the incretin pathway, which is why combining them produces additive weight reduction.
Evidence level: Early human data. Only small or early-phase studies in people so far. These are areas studied or reported, not promised effects.
Reported side effects and risks
- Native human amylin cannot be used as a drug because it aggregates into amyloid fibrils — pramlintide exists precisely because three proline substitutions were needed to prevent this. No regulator has approved it, the human evidence base is limited, and material sold under this name is research chemical supply with unverified identity, purity, sterility and dose accuracy.
- Islet amyloid deposition from amylin aggregation is implicated in beta cell loss in type 2 diabetes, making the native peptide a pathological as well as physiological agent.
- Amylin receptor agonists cause nausea and, with insulin, carry a severe hypoglycaemia risk — pramlintide carries a boxed warning for this.
- Material sold as amylin has no legitimate use and its aggregation behaviour makes purity claims especially unreliable.
Sources
- PubMed research on amylin IAPP islet amyloid pramlintide · NIH · National Library of Medicine
- DrugBank record for pramlintide · DrugBank
- Active clinical trials for pramlintide · U.S. National Library of Medicine
Track Amylin in Peptide Vault
Log every dose, set reminders on your own schedule, rotate injection sites and keep your vials organized. Peptide Vault records what you enter. It doesn't recommend compounds or doses. iPhone, on-device.
Related compounds
Amylin FAQ
What is Amylin?
Amylin is a 37-amino-acid hormone co-secreted with insulin by pancreatic beta cells. Native human amylin aggregates into amyloid fibrils, which is why the approved drug pramlintide is a modified analogue rather than the hormone itself.
How does Amylin work?
Amylin acts at amylin receptors — calcitonin receptors complexed with receptor activity-modifying proteins — in the area postrema. It slows gastric emptying, suppresses postprandial glucagon secretion and promotes satiety, complementing insulin's action on glucose disposal. Human amylin is intrinsically amyloidogenic, forming the islet amyloid deposits characteristic of type 2 diabetes.
Is Amylin FDA approved?
No. Amylin is a research compound and not approved by the FDA for human use. Evidence level: early human data. Only small or early-phase studies in people so far.
What is the half-life of Amylin?
Reported half-life: Approximately 13 minutes.
How is Amylin taken?
Not used therapeutically in native form.
What side effects have been reported with Amylin?
Reported in the sources: Native human amylin cannot be used as a drug because it aggregates into amyloid fibrils — pramlintide exists precisely because three proline substitutions were needed to prevent this. No regulator has approved it, the human evidence base is limited, and material sold under this name is research chemical supply with unverified identity, purity, sterility and dose accuracy; Islet amyloid deposition from amylin aggregation is implicated in beta cell loss in type 2 diabetes, making the native peptide a pathological as well as physiological agent; Amylin receptor agonists cause nausea and, with insulin, carry a severe hypoglycaemia risk — pramlintide carries a boxed warning for this; Material sold as amylin has no legitimate use and its aggregation behaviour makes purity claims especially unreliable.
Educational summary compiled from the sources listed above. Not medical advice. Peptide Vault does not sell, source or recommend any compound. Talk to a qualified clinician before starting or changing anything.